Lumiprobe Corporation
115 Airport Dr Suite 160
Westminster, Maryland 21157
USA
Phone: +1 888 973 6353
Fax: +1 888 973 6354
Email: order@lumiprobe.com

Cabozantinib

http://www.lumiprobe.com/p/cabozantinib-1140909-48-3

Cabozantinib is a dual mechanism inhibitor that targets MET receptor tyrosine kinase and vascular endothelial growth factor receptor 2 (VEGFR2). The drug is used for the treatment of several types of oncological diseases, including renal cell carcinoma (RCC) (including in combination with nivolumab), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC), and neuroendocrine tumors (NETs). The compound is also utilized in research to evaluate its efficacy and safety in other disease types, as well as to study mechanisms of therapy resistance.

This product is intended for research use only.



Structure of Cabozantinib

General properties

Appearance:	off-white powder
Molecular weight:	635.60
CAS number:	1140909-48-3 (malate); 849217-68-1
Molecular formula:	$C_{32}H_{30}FN_3O_{10}$
Solubility:	DMSO
Quality control:	NMR ^1H and HPLC-MS (98+%)
Storage conditions:	24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Desiccate.
Legal statement:	For research use only, we do not sell to patients, not for medical use.